Catalyst Funds Management’s ResMed RMD Stock Holding History

Catalyst Funds Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,859	Closed	-$2.62M	–	694
2025 Q4	$2.62M	Sell	10,859 -8,400	-44%	-$2.15M	0.61%	34
2025 Q3	$5.27M	Buy	+19,259	New	+$5.26M	0.8%	21
2024 Q4	–	Sell	-800	Closed	-$195K	–	1077
2024 Q3	$195K	Buy	800 +100	+14%	+$22.3K	0.04%	299
2024 Q2	$134K	Buy	+700	New	+$142K	0.04%	246

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catalyst Funds Management's RMD Position: Q1 2026 in Review

Catalyst Funds Management sold out of ResMed (RMD) in Q1 2026, closing a stake of 10,859 shares — an estimated $2.62M sold.

Catalyst Funds Management first reported a position in RMD in Q2 2024 and held it in 4 quarters. The position peaked at $5.27M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Catalyst Funds Management reported no remaining ResMed position as of Q1 2026 after selling out during the quarter.
Catalyst Funds Management sold 10,859 ResMed shares in Q1 2026, an estimated $2.62M.
Catalyst Funds Management first reported a position in ResMed in Q2 2024 and held it in 4 quarters.
Catalyst Funds Management's ResMed position peaked at $5.27M in Q3 2025.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.